Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg
Code effective Jul 01, 2026
HCPCS Section
Miscellaneous Services (Temporary Codes)
Q5098 is a valid 2026 HCPCS code meaning Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg or (Inj ustekinumab-srlf, 1 mg) for short. HCPCS Q5098 has been effective since 07/01/2026 and applies to Medical care.
|
HCPCS Level II Code Section Q - Miscellaneous Services (Temporary Codes) |
|
| HCPCS Code | Q5098 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
51 - Drugs
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| ASC payment group code | Effective Jul 01, 2026 - This procedure is approved to be performed in an ambulatory surgical center. |
| BETOS2 code | O1E - Other drugs |
| HCPCS Action code | P - Payment change (MOG, pricing indicator codes, anesthesia base units,Ambulatory Surgical Centers) |
| Type of service | 1 - Medical care |
| Effective date | Effective Jul 01, 2026 |
| Date added | Added Jul 01, 2025 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 7/13/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.